<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00888342</url>
  </required_header>
  <id_info>
    <org_study_id>GK-61</org_study_id>
    <secondary_id>2008/2/0083 (LHL)</secondary_id>
    <secondary_id>2688 (BIOBANK)</secondary_id>
    <secondary_id>6.2009.10 (REK)</secondary_id>
    <nct_id>NCT00888342</nct_id>
  </id_info>
  <brief_title>Changes in Blood Gases, Disturbance of Breath During Sleep and Cardiovascular Co-morbidity in COPD Patients</brief_title>
  <official_title>A Study of Changes in Blood Gases, Disturbance of Breath During Sleep and Cardiovascular Co-morbidity in Patients With COPD in Different Stages of the Disease, and the Effect of Alcohol, Supplementary Oxygen and Zopiclone on These Changes.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LHL Helse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stiftelsen Helse og Rehabilitering</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Landsforeningen for hjerte og lungesyke (LHL)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Akershus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ResMed</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>LHL Helse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Respiration failure type 2 is loss of the lungs ability to take up oxygen (O2) and get rid of
      carbon dioxide (CO2). The diagnosis is based on blood gas measurement of pressures of O2 and
      CO2. Patients with COPD is often seen to have co-morbidity with cardiac diseases. Chronic
      systemic inflammation is seen in both COPD and cardiac diseases. The investigators will
      investigate the sleep quality, CO2-retention, O2-saturation, cardiac arrythmias and markers
      of inflammation in 120 patients with COPD in different stages of the disease. Our hypotheses
      are:

        -  that the first signs of respiration failure type 2 is seen during sleep with alteration
           of sleep patterns and greater and more long-lasting retention of CO2 in the blood
           compared to those with a normal lung function

        -  that the use of alcohol, zopiclone or supplementary oxygen will make these differences
           even greater

        -  that cardiac arrythmias correlates with hypoxemia

        -  that cardiac arrythmias and respiration failure correlates with degree of inflammation
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>transcutaneously measured pCO2 during sleep</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>cardiac arrythmias registered by Holter monitoring</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Pulmonary Disease</condition>
  <condition>Chronic Obstructive</condition>
  <condition>Hypercapnia</condition>
  <condition>Hypoxemia</condition>
  <condition>Arrhythmias, Cardiac</condition>
  <arm_group>
    <arm_group_label>1 supplementary oxygen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>participant receives supplementary oxygen one night, polysomnography with capnography will be compared to no treatment another night</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 Zopiclone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>participant receives 5 mg zopiclone one night, polysomnography with capnography will be compared to no treatment another night</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 Alcohol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>participant receives 0,5 mg alcohol /kg body weight before sleep one night, polysomnography with capnography will be compared to no intervention another night</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>supplementary oxygen</intervention_name>
    <description>Supplementary oxygen 2 L/min if SpO2 &lt; 90%. If SpO2 &lt; 90 % the oxygen dose is titrated until SpO2 reads 88-92%. For patients on LTOT the oxygen dose is doubled for intervention.</description>
    <arm_group_label>1 supplementary oxygen</arm_group_label>
    <other_name>100% oxygen gas with continous flow from wall outlet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zopiclone</intervention_name>
    <description>5 mg sedative given approximately 1 hour before sleep</description>
    <arm_group_label>2 Zopiclone</arm_group_label>
    <other_name>Imovane, Zopiklon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>alcohol</intervention_name>
    <description>5 mg alcohol/kg body-weight approximately 1 hour before sleep</description>
    <arm_group_label>3 Alcohol</arm_group_label>
    <other_name>96% ethanol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  COPD (FEV1 &lt; 80 % of pred. and FEV1/FVC &lt; 0,7)

        Exclusion Criteria:

          -  other serious disease (like lung cancer, sarcoidosis, restrictive lung disease)

          -  exacerbation of COPD within 3 weeks before inclusion

          -  coronary heart disease with unstable angina pectoris or myocardial infarction within 3
             months of incl.

          -  uncontrolled hypertension

          -  cerebral infarction

          -  neurological, muscular or skeletal disease/disorder that affect abdominal- and/or
             thoracal movements (kyphoscoliosis, paresis, etc)

          -  unstable diabetes mellitus or signs of organ failure (anaemia, kidney failure, liver
             failure, etc)

          -  misuse/dependency of alcohol, sedatives, neurostimulating or narcotic drugs)

          -  obstructive sleep apnoea/hypopnoea syndrome

          -  using CPAP/BiPAP or home respirator

          -  pregnancy

          -  if PSG shows AHI &gt; 30, or if patient becomes acutely ill between the nights with PSG,
             he/she will be withdrawn from the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nils H Holmedahl, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>LHL Helse</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Glittreklinikken</name>
      <address>
        <city>Hakadal</city>
        <state>Akershus</state>
        <zip>1485</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glittreklinikken</name>
      <address>
        <city>Oslo</city>
        <state>Hakadal</state>
        <zip>1485</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2009</study_first_submitted>
  <study_first_submitted_qc>April 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2009</study_first_posted>
  <last_update_submitted>May 15, 2012</last_update_submitted>
  <last_update_submitted_qc>May 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary Disease</keyword>
  <keyword>Chronic Obstructive</keyword>
  <keyword>Hypercapnia</keyword>
  <keyword>Hypoxemia</keyword>
  <keyword>Arrhythmias, Cardiac</keyword>
  <keyword>Polysomnography</keyword>
  <keyword>Capnography</keyword>
  <keyword>Electrocardiography, Holter</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
    <mesh_term>Hypercapnia</mesh_term>
    <mesh_term>Arrhythmias, Cardiac</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>Zopiclone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

